Gheuens Sarah sold $296K of AGIO
Gheuens Sarah (Chief Medical Officer) sold 7,866 shares of AGIOS PHARMACEUTICALS, INC. (AGIO) at $37.69 ($0.30M total) on 2026-10-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is a routine insider transaction with modest dollar value, offering limited trading insight.
Market read
A small insider sell that may cause slight short‑term pressure but is unlikely to drive significant price movement.
What to watch
Potential upcoming clinical data releases could offset any negative sentiment from the sale.
Background
Form 4 filing by AGIO's CMO under a pre‑arranged 10b5‑1 plan.
Ticker impact
Chief Medical Officer sold 7,866 shares for $296K via a 10b5-1 plan, reducing holdings to 54,645 shares.
likely modest downward pressure as market prices in the insider sell.
The sale is a primary Form 4 filing, but the amount is modest and unlikely to move the stock significantly.
Market effects
Minimal impact on biotech sector; typical insider sales are routine.
No regional effect beyond the company.
Limited to investors tracking AGIO.
Counterpoint
The sale may be unrelated to company fundamentals and could be a routine liquidity move.
Key entities
- OfficerGheuens Sarah
Chief Medical Officer of Agios Pharmaceuticals.


